As per reports, Johnson & Johnson’s (JNJ) two-dose experimental vaccine for Ebola in the European Union has received approval from the European health regulators. The vaccine is prepared to target the Ebola strain that causes the disease in most people, J&J submitted the approval application for the vaccine to the European Medicines Agency last year November.
Approval by the European can help J&J’s efforts to spread access of the vaccine to vulnerable countries and to enable registration in African countries, as per reports. Democratic Republic of Congo (DRC) has reported more than 3,400 people infected with the ongoing Ebola virus outbreak. The first Ebola outbreak in DRC killed more than 11,300 in 2013-16.
In February, J&J informed that it undergoing development of a coronavirus vaccine program with the same technologies as used in the experimental Ebola vaccine and the company has also entered a manufacturing deal with Emergent BioSolutions Inc to produce more than 1 billion doses of its COVID-19 vaccine candidate which is expected to begin human trials by September.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.